Pathophysiology and Imaging Findings of Bile Duct Necrosis: A Rare but Serious Complication of Transarterial Therapy for Liver Tumors

Satoshi Kobayashi *, Kazuto Kozaka, Toshifumi Gabata, Osamu Matsui, Wataru Koda, Miho Okuda, Kenichiro Okumura, Takumi Sugiura and Takahiro Ogi

Department of Radiology, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara Machi, Kanazawa 920-8641, Japan; k-kozaka@staff.kanazawa-u.ac.jp (K.K.); gabata@med.kanazawa-u.ac.jp (T.G.); matsuio@med.kanazawa-u.ac.jp (O.M.); wkoda@staff.kanazawa-u.ac.jp (W.K.); okudamiho@staff.kanazawa-u.ac.jp (M.O.); okumurak@staff.kanazawa-u.ac.jp (K.O.); tsugiura@stu.kanazawa-u.ac.jp (T.S.); ogi@staff.kanazawa-u.ac.jp (T.O.)

* Correspondence: satoshik@staff.kanazawa-u.ac.jp; Tel.: +81-76-265-2500

Received: 17 August 2020; Accepted: 9 September 2020; Published: 11 September 2020

Simple Summary: Bile duct necrosis (BDN) is rare but serious complication of transarterial therapy for liver tumors. During development of BDN, ischemia of the peribiliary vascular plexus (PBP) induces the disruption of the bile duct epithelial protection mechanism, causing necrosis of the surrounding tissue by the detergent action of exuded bile acids, and eventually a biloma forms. Once BDN starts, persistent tissue damage to the surrounding bile duct is induced by imbibed bile acids, and portal vein thrombosis may also be observed. On CT images, BDN shows similar findings to intrahepatic bile duct dilatation, and, therefore, it is sometimes misdiagnosed. Clinicians should be aware that although BDN and biloma can usually be treated conservatively, in the presence of symptoms such as moderate or severe infection or interval growth of the biloma, prompt treatment is essential to avoid lethal abscess formation and sepsis.

Abstract: Bile duct necrosis (BDN) with biloma formation is a type of ischemic bile duct injury that is one of the serious complications associated with transarterial therapies, such as transcatheter chemoembolization therapy (TACE), and radioembolization for hepatocellular carcinoma (HCC) and hepatic arterial infusion chemotherapy (HAIC) for metastatic liver cancer from colorectal carcinoma. In terms of the occurrence of BDN and subsequent biloma formation, ischemic injury to the peribiliary vascular plexus (PBP), the supporting vessel of bile duct epithelium, is thought to be intimately associated. In this paper, we first describe the anatomy, blood supply, and function of the intrahepatic bile duct, and then illustrate the pathophysiology of BDN, and finally present the imaging findings of BDN. Under the process of BDN formation, ischemia of the PBP induces the disruption of the bile duct epithelial protection mechanism that causes coagulation and fibrinoid necrosis of the surrounding tissue by the detergent action of exuded bile acids, and eventually a biloma forms. Once BDN occurs, persistent tissue damage to the surrounding bile duct is induced by imbibed bile acids, and portal vein thrombosis may also be observed. On pre-contrast and contrast-enhanced computed tomography (CT), BDN shows similar findings to intrahepatic bile duct dilatation, and, therefore, it is sometimes misdiagnosed. Differentiation of imaging findings on CT and ultrasound (US)/magnetic resonance (MR) imaging/MR cholangiopancreatography (MRCP) is important for correct diagnosis of BDN.

Keywords: hepatocellular carcinoma; chemoembolization; bile duct necrosis; peribiliary vascular plexus
1. Introduction

Bile duct necrosis (BDN) is a subtype of ischemic bile duct injury (synonym of ischemic cholangiopathy) [1]. BDN is known to occur as a side effect of transcatheter therapies that are intended to treat hepatocellular carcinoma (HCC) and metastatic liver cancer (MLC) [2–7]. Progression of BDN causes peribiliary tissue necrosis and eventually induces biloma formation [8,9]. If biloma infection occurs by ascending cholangitis, it can form a liver abscess and cause severe sepsis or even death [10–12].

Bile duct ischemia is thought to be involved in the development of BDN, but there are few reports that review its pathophysiology [3,8,10]. To date, there have been almost no detailed reviews of the imaging findings of BDN after transcatheter therapy or morphological changes in the liver after development of BDN [9,13,14].

In this article, we first review the anatomy and function of the intrahepatic biliary system and its supplying vessel, the peribiliary vascular plexus (PBP). Then, we describe the pathophysiology and imaging findings of BDN after transcatheter therapy, and the changes in liver imaging over time after the development of BDN. Lastly, we describe the therapeutic approach to BDN that occurs during the course of transcatheter therapies for liver tumors.

2. Anatomy of the Intrahepatic Bile Duct System

Intrahepatic biliary tracts are classified as intrahepatic large bile ducts and small bile ducts [15]. Intrahepatic large bile ducts include right and left hepatic ducts (>800 μm), segmental ducts (400–800 μm), and area ducts (300–400 μm). Small bile ducts include septal bile ducts (100–300 μm), interlobular bile ducts (15–100 μm), and bile ductules (<15 μm) (Figure 1).

![Image illustrates the size and characteristics of the intrahepatic bile ducts.](Figure 1)
intrahepatic bile ducts have peribiliary glands in the wall [16]. Small bile ducts are composed of a cuboidal epithelium. The bile ducts that can be identified by needle biopsy are interlobular bile ducts and bile ducts that are smaller than interlobular bile ducts, whereas wedge biopsy can evaluate small bile ducts, such as septal bile ducts, which are larger than bile ducts that can be identified by needle biopsy.

The intrahepatic and extrahepatic biliary tract is supplied and nourished by a network of fine vessels called the PBP [17–19]. Afferent vessels of this plexus derive from hepatic arterial branches, the gastroduodenal artery, the posterior superior pancreaticoduodenal artery, and the retroportal artery, and this plexus drains into the portal venous system or directly into hepatic sinusoids [9] (Figure 2).

**Figure 2.** Schematic diagram of the intrahepatic bile duct and peribiliary vascular plexus (PBP). The larger intrahepatic biliary tract is supplied and nourished by a network of fine vessels called the PBP. Afferent vessels of this plexus derive from hepatic arterial branches, and this plexus drains into the portal venous system or directly into the hepatic sinusoids.

Histologically, the PBP is divided into an inner, intermediate, and outer layer [18]. In the large intrahepatic large bile ducts and septal bile ducts, the PBP shows a three-layer pattern, but around the smaller bile ducts, such as interlobular bile ducts, PBP shows no discernible layer formation (Figure 3). The inner layer of the PBP is a layer of capillaries that is observed just beneath the basement membrane of the bile duct epithelium (cholangiocytes). The outer layer is present in the periductal tissue and is
composed of arteries, veins, and capillaries. The intermediate layer vessels are in the duct walls and presumed to connect the inner and the outer layer.

Figure 3. Schematic diagram and histopathologic image of PBP. (a) Schematic diagram of PBP. In the normal liver, the PBP around the large intrahepatic bile duct shows a three-layer pattern, i.e., the inner, the outer, and the intermediate layer. The inner layer of the PBP is observed just beneath the basement membrane of the bile duct epithelium, and the outer layer is present in the periductal tissue and is composed of arteries, veins, and capillaries. The intermediate layer vessels are in the duct walls and are presumed to connect the inner and the outer layer. (b,c) On photomicrography of the PBP in the normal liver (b), the inner, outer, and intermediate layer vessels of the PBP have narrow lumen and are arranged in an orderly fashion. In contrast, the PBP in the cirrhotic liver has dilated lumen and is arranged irregularly (c), which represents increase in collateral flow by portal hypertension. (Immunostaining of factor VIII; original magnification, (b): ×40, (c): ×100).

The PBP plays a fundamental role in supporting the secretory and absorptive functions of the biliary epithelium [20]. In the cirrhotic liver, the PBP works as the collateral pathway of portal hypertension and shows marked dilatation and an increase in numbers [18]. In contrast, after repeated transcatheter chemoembolization therapy (TACE) for the treatment of HCC in the cirrhotic liver, the PBP shows a decrease in numbers, especially in the inner layer vessels [21].
3. Function of the Bile Duct and the Significance of the PBP

Although the main bile production site is hepatocytes, around 40% of the total bile production is of ductal origin in humans [22]. Secretory functions are mainly performed by cholangiocytes (synonym of “bile duct epithelium”) lining the interlobular, septal, and major bile ducts, as they express the appropriate ion transport systems and hormone receptors in polarized domains of the plasma membrane [15].

Bile acids (BAs) are major organic solutes in the bile and are involved in several important functions in the liver and intestine. BAs are steroid compounds that are biosynthesized by the liver from cholesterol. The main action of BAs is to activate lipases and form micelles along with dietary lipids to promote their absorption, but they also have an important role in regulating cholesterol metabolism via the conversion of cholesterol to BAs. Discharged from the bile ducts to the duodenum, most of the BAs that reach the ileum are reabsorbed by the ileum mucosa and repeat the enterohepatic circulation. BAs may disrupt cell membranes through their detergent action on lipid components, and they can promote the generation of reactive oxygen species and eventually cause cellular necrosis and apoptosis [23]. There are some mechanisms to protect the bile duct epithelium from the aggression of BAs (Table 1, Figure 1).

| Mechanism                                | Notes                                                                 |
|------------------------------------------|----------------------------------------------------------------------|
| Cholehepatic shunt pathway               | Bile duct epithelium absorbs BAs through the BA transporter and excretes them into the peribiliary vascular plexus. They are then transported to hepatocytes |
| Mucin secretion from peribiliary glands  | Limited to large bile ducts which have peribiliary glands around the duct wall |
| Bicarbonate secretion by bile duct epithelium (HCO$_3^-$ umbrella) | Limited to small bile ducts                                           |
| Phospholipid secretion from hepatocytes  | May depend on hepatocyte functional state                             |

Physiologically, the balance of BA influx and efflux in cholangiocytes is maintained by BA transporters to avoid accumulation of toxic BAs. BAs are absorbed by cholangiocytes and subsequently excreted into the PBP, and then followed by reabsorption by hepatocytes and re-excretion in the form of bile. This recycling of BAs between hepatocytes and cholangiocytes through PBP is referred to as the cholehepatic shunt pathway [24].

In large bile ducts, the peribiliary glands, which are located in the bile duct wall, secrete mucin into bile duct lumen and are involved in protecting the bile duct epithelium [16]. In contrast, the small bile ducts do not have peribiliary glands and do not have mucin secretion capacity. In addition, the PBP is also underdeveloped in small bile ducts, so protection by the cholehepatic shunt pathway is not expected. Therefore, in small bile ducts, bile duct epithelial cells secrete bicarbonate to protect bile duct epithelial cells from highly cytotoxic BAs, which is called the biliary HCO$_3^-$ umbrella [25]. Anion exchanger2 (AE2) is involved in this mechanism. AE2 expression is down-regulated in primary biliary cholangitis (PBC), a disease caused by the destruction of small bile ducts [26]. The phospholipids, which are secreted by hepatocytes, provide another bile duct epithelial protection mechanism [27]. Phospholipids are secreted into bile in humans by the multidrug resistance 3 (Mdr3) P-glycoprotein, which is located in the canalicular membrane of hepatocytes.

Under normal circumstances, the detrimental effects of BAs are largely antagonized by phospholipids and the formation of mixed micelles in bile. However, if the secretion of phospholipids is depressed, the toxicity of bile salts is not neutralized, which might induce structural and functional injury to the cellular membranes of the bile duct epithelium and cause cellular necrosis and apoptosis [23].
4. Pathophysiology of BDN after Transcatheter Therapy

BDN is one form of ischemic bile duct injury \[1\]. Ischemic bile duct injury may show the following pathologic changes: bile duct necrosis, bile leakage, biloma, and bile duct fibrosis or stenosis. Within ischemic bile duct injuries, BDN develops predominantly where there is an abrupt and complete interruption of arterial blood supply, such as hepatic artery thrombosis in a liver transplant recipient \[28\]. In contrast, bile duct stenosis develops where there is progressive injury to the hepatic arterioles, such as after repeated hepatic arterial infusion of anticancer drugs (HAIC).

TACE and HAIC have been used since the 1980s to treat advanced hepatocellular carcinoma (HCC) and liver metastasis from colorectal cancer \[2,6\]. BDN has been reported as a serious complication of these treatments \[2,3,6,7\].

Although biliary strictures are common biliary complication of ischemic bile duct injury, BDN and subsequent intrahepatic biloma formation are also important complications of transcatheter therapy for hepatic tumors \[1,10\]. In one autopsy study, the incidence of bile duct necrosis after transcatheter arterial chememoembolization (TACE) for HCC was 9% \[3\].

HAIC is a reasonable drug delivery system for patients with intrahepatic metastases and advanced HCCs. However, one study reported that bile duct abnormalities developed in 57% of patients either during HAIC or 1 to 12 months after treatment \[29\]. In addition, the incidence of BDN after HAIC for treatment of colorectal metastatic liver tumor was reported to be 1.8% \[6\].

In macroscopic specimens, BDN is recognized as a dark green, circular or tubular area centered on the portal tract in the cross-section of the liver (Figure 4a) \[3\]. In BDN with biloma formation, a necrotic bile duct showing dark green tubular structures is consecutive to biloma formation (Figure 4b).

![Figure 4. Bile duct necrosis (BDN). (a) Photograph of a gross specimen of the cut surface of the liver. There are round-shaped (arrow) and linear (arrow heads) dark green lesions in the right lobe of the liver. These images represent the cross-section and longitudinal cross-section of the necrotic bile ducts. (b) Photograph of a gross specimen of the cut surface of the liver. The necrotic bile duct, which shows a dark green tubular structure, is consecutive to the biloma, which shows a large dark green cystic mass like a lesion (curved arrows).](image)

Histopathologically, peri-bile duct tissue, including the portal tract contents and surrounding hepatic parenchyma, are imbibed by bile and show necrotic change, including coagulation necrosis and fibrinoid necrosis (Figure 5) \[3,9,10\].
Inflammatory cell infiltration is also observed in peri-bile duct tissue [30]. The bile ducts are located at the center of the necrotic changes, and the lumen of the bile ducts is patently open. Therefore, the bile produced in the distal liver is excreted through the open lumen of the necrotic bile duct in the area of BDN and flows into the bile ducts of the proximal portion of the liver. This is strongly related to the persistent exacerbation of bile duct necrosis, which leads to biloma formation. Immunostaining of the vascular endothelium shows that PBP vessels of adjacent to the BDN area have disappeared or are markedly reduced (Figure 6) [3].

Generally, in the cirrhotic liver, the PBP is dilated and increased in both the inner and outer layers compared to the normal liver [3]. However, repeated TACE or HAIC can induce development
of vasculitis, which can lead to deterioration (reduction or loss) of PBP vessels, as well damage to the hepatic arterial branches. For a PBP that has been devastated by TACE, further TACE will result in disruption of PBP blood flow and ischemia and injury to the bile duct epithelium [3,10]. Similarly, repeated HAICs can also lead to bile duct epithelial injury due to the deterioration of the PBP. The decrease in or loss of PBP blood flow causes dysfunction of bile duct epithelial cells and reduces the secretion of phospholipids from hepatocytes, which work to protect bile duct epithelial cells [27]. Therefore, bile duct epithelial cells are unable to protect themselves from the detergent action of BAs, leading to cell necrosis and apoptosis. Reduced PBP blood flow also causes dysfunction of the cholehepatic shunt pathway, which transports BAs absorbed by cholangiocytes to the hepatocytes [24]. Consequently, injury to the bile duct epithelium becomes more severe.

Sakamoto et al. stated that the interaction between two factors is important for the development of BDN (Figure 7) [10].

Figure 7. Schematic diagram of the development of BDN and subsequent biloma formation. In liver cirrhosis, both inner and outer vessels of PBP show dilatation and increased in number (A). After repeated TACE, the inner layer of PBP vessels are damaged and decreased in number (B). Once ischemic bile duct epithelial injury is caused by PBP disorder, toxic bile acids (BAs) exude to the bile duct wall and show necrotic change in and around bile duct, which is the early stage of BDN (C). If the progressive necrosis of peri-bile duct tissue caused by exuded BAs involves the portal venous branch, portal vein thrombosis can be easily developed (D). If ischemic bile duct injury downstream of the BDN site occurs, stenosis of the downstream bile duct may induce intrahepatic bile stasis, which causes an increase in intrabiliary pressure at the bile duct epithelial injury site, which leads to increased leakage of BAs into the surrounding tissues and causes overt biloma formation (E).

One factor is bile duct epithelial injury caused by a PBP disorder in BDN site. The other factor is the stenosis of the downstream bile duct caused by ischemic bile duct injury downstream of the BDN...
Stenosis of the downstream bile duct may induce intrahepatic bile stasis and cholangitis. Bile stasis causes an increase in intrabiliary pressure at the bile duct epithelial injury site, which leads to increased leakage of BAs into the surrounding tissues through the bile duct epithelium and extensive necrosis of structures in the portal tract and adjacent hepatocytes due to the toxic detergent action of BAs [31]. Consequently, overt BDN which is recognized on diagnostic imaging is developed.

BDN is less frequent in liver transplantation. This is due to the fact that retrograde blood flow from the portal system maintains PBP blood flow, even after the disruption of hepatic arterial blood flow toward the PBP in the case of arterial blood flow impairment during liver transplantation [32–34]. In contrast, in TACE and HAIC, bile duct epithelial injury is more pronounced because the PBP itself is impaired and blood flow within the PBP is intercepted [3,35]. TACE for liver metastases is more likely to produce BDN than TACE for HCC [36]. There are two reasons for this. One reason is that, compared to hypervascular HCC, liver metastases are hypovascular, and drug accumulation in the peritumoral normal liver is greater than drug accumulation within the tumor. The other reason is that the background liver condition in metastatic liver cancer is usually normal, and the normal liver is prone to PBP injury because the PBP in the normal liver is not as dilated and enlarged as observed in cirrhotic liver [3].

Damage to the bile duct epithelium by BAs causes bile to leak into the peri-bile duct tissue, leading to progressive necrosis of the peri-bile duct tissue. At this moment, the portal vein that runs along the bile ducts is easily damaged because of its thin wall, and portal vein thrombosis can easily be developed (Figure 8) [36].

![Figure 8. Photomicrograph of BDN. Coagulation necrosis is observed within the portal tract (arrows). The lumen of the necrotic bile duct is open (*). Thrombosis is observed in the portal venous branch (arrowhead). Embolic material is observed in the hepatic arterial branch (curved arrow). (H&E stain; original magnification, ×40.).](image)

As a result, portal venous blood flow to the periphery of the liver is disrupted at the BDN site. In contrast, the hepatic artery running along the necrotic bile duct is less vulnerable to damage than the portal vein because of the thick fibromuscular layer of the arterial wall. Therefore, hepatic artery occlusion occurs at a more advanced (later) stage of BDN than portal vein occlusion.

Bile inflow from the peripheral part of the liver is persistent in bile ducts that have developed BDN. However, bile duct stenosis is present in the bile ducts downstream portion of the BDN site. This causes increased intra-bile duct pressure and continuous leakage of BAs at the site of bile duct
epithelium damage. Therefore, necrobiotic change in the periductal tissue adjacent to the damaged bile duct persists, even after discontinuance of therapeutic interventions such as TACE and HAIC, which damage the bile duct and eventually form a biloma. When the portal tract and its surrounding components, such as the canal of Hering and hepatic progenitor cells, become necrotic due to the toxic effect of BAs exude from BDN, the liver cannot regenerate in this area and gradually shows atrophy. This may have a synergistic effect on the hepatic parenchymal atrophy caused by portal blood flow damage due to the exuded BAs.

Intrahepatic bile duct dilatation and cholestasis are not seen upstream of the BDN site because the bile duct lumen remains open in the bile duct necrosis area. However, at the site of BDN, occlusion of the portal vein and hepatic artery occurs, which results in peripheral hepatic atrophy.

In the case of retrograde infection from the gastrointestinal tract, the BDN site and/or biloma become a liver abscess, which may result in lethal sepsis [10–12].

5. Imaging Findings of BDN

BDN is usually depicted on CT scan for closer examination of laboratory data abnormality, i.e., marked elevation of serum alkaline phosphatase (ALP) either with or without increased serum bilirubin during the course of repeated TACE or HAIC [27,33]. However, it is difficult to make an accurate diagnosis of BDN on CT without sufficient knowledge, because it shows similar findings to that of intrahepatic bile duct dilatation, especially at the early stage.

Here, we present for the first time the CT findings of BDN. We also describe the findings of other imaging modalities that may be useful in confirming the imaging diagnosis of BDN. Finally, we describe the subsequent CT course of the liver after the occurrence of BDN.

- CT findings of bile duct necrosis

On pre-contrast and contrast-enhanced CT (CE-CT), BDN shows a linear hypodense structure along with a portal tract which looks like “intrahepatic bile duct dilatation” (Figure 9) [10,36]. The diameter of the lesion may show irregularity and might show findings similar to the “beaded-like appearance” observed in primary sclerosing cholangitis. Often, this finding is misdiagnosed as intrahepatic bile duct dilatation because the reason for the CT examination is a close examination of the cause of liver dysfunction, including increased serum bilirubin.

Figure 9. Portal phase image of contrast-enhanced CT of BDN and the biloma after transarterial therapy. A hypodense tubular structure (arrows) is connected to the large cystic lesion (*) in the lateral segment of the liver. The tubular structure is BDN of the anterolateral segment (S3) and the cystic lesion is biloma.
Structures with similar imaging findings in the liver after TACE have been reported under the following names: branched biloma [12], focal or multiple intrahepatic bile duct dilatation [11], and bile duct dilatation with extravasated bile collection along the portal tract [37]. Each of these is the same pathological condition as BDN.

Since BDN represents a precursor lesion to biloma, intrahepatic biloma formation sometimes coexists with BDN. In such cases, the abovementioned linear hypodense structure, along with the portal tract, connects with the biloma. Advanced BDN can lead to portal vein thrombosis (Figure 10), and may cause segmental staining associated with portal vein perfusion disorders on the arterial phase of contrast-enhanced CT images. After repeated HAIC, BDN cases may show a thickening of the arterial wall and elevated fat density around the artery with catheter insertion, such as the common hepatic artery or proper hepatic artery, which is a finding of hepatic arterial damage caused by HAIC (Figure 11) [29].

**Figure 10.** Equilibrium phase image of a contrast-enhanced CT of BDN. A hypodense tubular structure (arrows) is observed in the hepatic hilum of the right lobe. Enhancement of the right main portal branch is discontinued (*), which represents thrombotic obstruction of the portal vein caused by BDN. (Curved arrow is the biloma.).

**Figure 11.** Arterial wall thickening (arrows) observed around the catheter which is inserted into the common hepatic artery for hepatic arterial infusion chemotherapy for the treatment of metastatic liver cancer.
• Ultrasound (US) findings of bile duct necrosis

BDN shows similar findings to intrahepatic bile duct dilatation on both pre-contrast CT and CE-CT, but this structure is “peribiliary necrotic tissue” rather than a “fluid-filled dilated duct” and it is not depicted on US as an echo-free duct-like structure.

In BDN, the damaged larger portal tracts are observed as slightly hyperechoic structures without a dilated intrahepatic bile duct (Figure 12) [9]. It is important to recognize the differences between CT and US findings for correct diagnosis of BDN.

![Comparison between CT and ultrasound (US) findings of BDN. (a) On contrast-enhanced CT, a hypodense thick tubular structure (arrow) is observed in the hepatic hilum of the right hepatic lobe, and in the left lateral segment, a similar hypodense thin tubular structure (arrowheads) is observed. Although these tubular hypodense structures look like dilated intrahepatic bile ducts, the right lobe lesion is BDN and the left lateral lobe lesion is bile duct dilatation. (b) On US images of the right hepatic lobe, no dilated bile ducts are observed in the portal tract. The portal tract shows iso- to slightly hyper-echo compared to the surrounding liver parenchyma (arrows). This US finding is inconsistent with the CT finding. (c) In the US image of left lateral lobe of the liver, a slightly dilated echo-free tubular structure (arrows) is observed along the arterial branch, which represents intrahepatic bile duct dilatation. As indicated on Figure 12b, BDN is iso- to slightly hyper-echo compared to the surrounding liver parenchyma and shows discrepancy with the CT finding.](image)

• T2-weighted MR findings of bile duct necrosis

On T2-weighted MR images, BDN does not show marked high intensity, but slightly high intensity, which represents portal tract damage caused by imbibed bile salt, rather than a fluid-filled dilated bile duct (Figure 13). On MR cholangiopancreatography (MRCP), a necrotic portion of BDN shows variable signal intensities depending on the ratio of water to necrotic tissue (with/without hemorrhage).
contents on heavy-T2 weighted images, which reflects the absence of intrahepatic bile duct dilation at the BDN site (Figure 14). Recognizing the difference between the T2-weighted MR images and CT findings provides confidence in making a diagnosis of BDN and not intrahepatic bile duct dilatation.

**Figure 13.** Comparison between CT and T2-weighted MRI findings of BDN. (a) On contrast-enhanced CT, a hypodense irregular tubular structure (*) is observed in the left lateral segment of the liver. Although this tube-like structure looks like irregularly dilated intrahepatic bile ducts, it is BDN. Biloma formation (arrow) is observed at the peripheral portion of the lateral segment which is connected to BDN. On the hepatic hilum, slightly dilated right and left hepatic ducts are observed (arrowheads). (b) On T2-weighted MRI, BDN (*) and biloma (arrow) on the left lateral lobe of the liver do not show marked hyperintensity like the hepatic ducts (arrowheads), but instead show slight hyperintensity. This finding suggests that BDN and biloma are not pure fluid-filled spaces, but “necrotic tissue”. (Figure 13a is same figure as Figure 9. It is presented for comparison with Figure 13b).

**Figure 14.** Comparison between CT and MR cholangiopancreatography (MRCP) findings of BDN. (a) On contrast-enhanced CT, a hypodense tubular structure is observed in the hilar area of the right liver lobe (arrow). Adjacent to this tubular structure, a large hypodense mass is observed in the medial segment of the liver (*). These structures are BDN (arrow) and a biloma (*). A dilated intrahepatic bile duct is also observed in the lateral segment of the liver (arrowheads). (b) On MRCP, although dilated intrahepatic bile ducts in the left lateral lobe of the liver are clearly observed, bile ducts in the hilar region and right hepatic lobe are unclear (arrow). Furthermore, the biloma in the medial segment of the liver is not clearly depicted on MRCP (*).

- Hepatocyte-specific MR contrast agent and bile duct necrosis

Gd-EOB-DTPA (EOB) is a hepatobiliary MR contrast agent for T1-weighted imaging that is taken up by the organic anion transporters OATP1B1/B3 into hepatocytes and excreted through the biliary pathway according to the efficiency of each hepatocyte [38,39]. About 20 min after intravenous administration, EOB is taken up by hepatocytes, and the hepatic parenchyma shows hyperintensity and
a liver lesion which consists of cells/tissue without hepatocellular origin which shows hypointensity because of no uptake of EOB in this area. Interestingly, in BDN, EOB gradually oozes out through the necrotic bile duct towards the surrounding periductal necrotic tissue, and the necrotic area shows marked hyperintensity on the super-delayed phase (70 min after intravenous injection) (Figure 15). The super-delayed phase image of Gd-EOB-DTPA on enhanced MRI might have potential to clearly depict the bile duct necrosis area by the exudation of EOB toward the damaged liver tissue [40].

![Figure 15. MR findings of BDN.](image)

**Figure 15.** MR findings of BDN. (a) On T2-weighted MRI, BDN (arrow) on the left lateral lobe of the liver shows thick tubular hyperintensity, and the degree of hyperintensity is not so high compared to the cerebrospinal fluid observed in the spinal canal (curved arrow). (b) In the hepatobiliary phase of Gd-EOB-DTPA (EOB), which is 20 min after intravenous (iv) administration, the BDN site shows hypointensity compared to the background liver (arrows). Usually, in this phase, the intrahepatic bile duct shows hyperintensity because of secretion of EOB to the bile. (c) About 70 min after intravenous administration of EOB, the BDN area shows marked hyperintensity (arrow), which represents EOB exuding into the BDN region and being retained at the necrotic area.

The diagnostic algorithm of BDN during the course of repeated TACE or HAIC for treatment of a liver tumor is shown on Figure 16.

![Figure 16. Diagnostic algorithm of BDN.](image)

**Figure 16.** Diagnostic algorithm of BDN during the course of repeated transcatheter chemoembolization therapy (TACE) or hepatic arterial infusion chemotherapy (HAIC) for treatment of a liver tumor.
6. Progression of Bile Duct Necrosis on Sequential CT Images

Because of the chemical toxicity of the imbibed BAs, BDN, including the surrounding liver damage, progresses even after the discontinuance of the TACE/HAIC. For example, periductal tissue damage progresses persistently, and about 90% of the cases show portal vein obstruction adjacent to BDN [36]. Disruption of portal vein blood flow leads to hepatic atrophy in the portal perfusion area.

7. Mimickers of “Bile Duct Necrosis” on Imaging

In this section, we review the disease and pathological conditions that may show similar imaging findings to that of BDN.

- Portal vein thrombosis

In adult patients, cirrhosis, hepatic tumor, hypercoagulable state, pancreatitis, inflammatory bowel disease, myelo-proliferating disease, and the post-abdominal surgery state are the main causes of portal vein thrombosis [41,42]. The thrombotic portal venous branch within a large portal tracts show tubular hypodense structures on CE-CT and might show findings that mimic BDN (Figure 17). In portal vein thrombosis, cavernous transformation of the portal vein is sometimes observed in portal vein thrombosis of the hepatic hilum area, especially in the chronic phase of portal vein thrombosis [43]. On arterial phase images on CE-CT, hepatic parenchyma, which is nourished by the thrombosed portal venous branch, shows segmental staining in portal vein thrombosis. Such segmental staining on the arterial phase image of CE-CT is generally not observed in BDN. However, in advanced BDN, secondary portal vein thrombosis might occur by toxic detergent reaction of BAs which infiltrate into the portal venous wall. In such cases, BDN also shows segmental staining on the arterial phase of CE-CT.

- Obstructive jaundice (bile duct dilatation)

Biliary obstruction caused by a tumor/stones in the lower biliary system blocks bile flow and shows bile duct dilatation in the upper part of the bile duct [44]. On pre-contrast CT and CE-CT, such dilated bile ducts observed in obstructive jaundice cases show hypointense tubular structures similar to BDN (Figure 18). However, usually in obstructive jaundice cases, it is easy to identify the cause of biliary obstruction, such as a common bile duct stone or a common bile duct carcinoma, on imaging in the downstream of the dilated bile duct with CT, MRI, and MRCP. In obstructive jaundice cases, the dilated bile duct is easily recognized on US and MRCP. In contrast, in BDN cases, the hypodense tubular structure observed on CT generally does not show typical findings of bile duct dilatation on US and
MRCP. Another important finding which can differentiate BDN and bile duct dilatation might be the extent of the hypodense tubular structure on CT. In BDN, generally, the hypodense tubular structure on CT is restricted to the necrotic area of the biliary tract. In contrast, in obstructive jaundice cases, hypodense tubular structures on CT are observed throughout the bile duct upstream of the biliary obstruction site and gradually taper off as they move toward the peripheral part of the liver.

**Figure 18.** Obstructive jaundice (intra- and extra-hepatic bile duct dilatation) observed in a 77-year-old man. (a) In the portal venous phase on contrast-enhanced CT, a dilated linear hypodense structure (arrows) is observed along the portal vein in the hepatic hilar area. (b) On MRCP, common bile duct obstruction caused by common bile duct carcinoma is observed (arrow). The upstream dilated bile ducts gradually taper as they move toward the peripheral part of the liver.

- **Peribiliary cyst**

Peribiliary cyst (PC) is a cystic dilatation of the peribiliary glands outside the intrahepatic large bile duct wall. PC is associated with polycystic liver and cirrhosis at a high rate [45]. It is also present in other chronic liver diseases, portal hypertension, and ductal plate malformation. PC observed in cirrhotic cases generally increases in number and size as the cirrhosis progresses. PC shows hypodensity, and a well-defined intrahepatic structure around the liver hilum on pre-contrast CT and CE-CT (Figure 19). PC shows marked hyperintensity on T2-WI MRI given its retention of cysts of the peribiliary glands. Although intrahepatic bile duct dilatation is observed only on one side along the portal vein, PCs are located bilaterally along the portal vein (Figure 19).

**Figure 19.** Peribiliary cyst observed in a 56-year-old man with cirrhosis. In the portal venous phase on contrast-enhanced CT, dilated multiple hypodense cystic structures (arrows) are observed along the left main portal vein and its branch in the hepatic hilar area. These structures are peribiliary cysts, showing cystic dilatation of the peribiliary glands around the large bile duct. Although this hypodense structure looks like intrahepatic bile duct dilatation, it is located bilaterally along the portal vein, unlike dilated bile duct (arrows).
• Caroli’s disease

Caroli’s disease (CD) is a rare congenital disorder of bile duct formation that develops as non-obstructive cystic dilation of the intrahepatic bile duct system [46]. CD shows autosomal recessive inheritance. Abnormal cystic dilatation of bile ducts in CD may distribute in a regional or diffuse manner. On CT, the lesion shows multiple hypodense rounded areas which are inseparable from the dilated intrahepatic bile ducts (Figure 20). The contrast-enhanced portal venous branch within the dilated intrahepatic duct is referred to as the “central dot sign” [47].

Schematic diagram of the pathological characteristics of BDN and its mimickers are shown on Figure 21.

Figure 20. Caroli’s disease in a 58-year-old man. In the equilibrium phase on contrast-enhanced CT, multiple hypodense cystic or tube-like structures (arrows) are observed throughout the liver. Contrast-enhanced portal venous branches (arrowheads) are observed in the center of the hypodense structure, which is called the “central dot sign”, a characteristic finding of Caroli’s disease.

Figure 21. Schematic diagram of the pathological characteristics which show a hypodense tube-like structure on pre-contrast-enhanced CT and contrast-enhanced CT in BDN and its mimickers.
8. How to Treat Bile Duct Necrosis

BDN is a preceding stage of overt biloma, also known as a branched-type biloma [8,12]. If BDN is detected on imaging during the course of repeated TACE or HAIC for treatment of a liver tumor, we should consider such cases as at high risk of overt biloma formation. In such cases, no additional TACE or HAIC should be performed [10]. When biloma occurs, conservative treatment is appropriate unless there are symptoms or interval increase in the biloma [10]. However, in 20–65% of biloma cases, symptoms such as mild to severe signs of infection or interval increase in the biloma are seen [10–12].

Even in symptomatic cases, the outcome of most intrahepatic biloma is not poor if prompt percutaneous drainage or surgical treatment is performed in addition to the use of antibiotics. The mortality rate of patients with biloma formation after TACE is about 5–10% [11,12]. Therefore, early detection of BDN and biloma on imaging and careful treatment might be mandatory to improve patient prognosis with repeated TACE or HAIC for liver tumors (Figure 22). Once infection of the biloma is suspected, prompt appropriate treatment should be considered to avoid treatment-related death [10].

Additional TACE sessions to the liver area with bile duct necrosis is high risk for occurrence of biloma and / or liver abscess.

Figure 22. Schematic diagram of the treatment strategy for BDN.

9. Conclusions

BDN and biloma formation is one of the serious complications of transcatheter therapy for hepatic malignancy. Ischemic injury of the PBP, the supportive vessel of the bile duct epithelium, is intimately associated with the formation of BDN and subsequent development of biloma. Once BDN occurs, persistent tissue damage to the surrounding bile duct is induced by imbibed bile juice, and portal vein thrombosis may also be observed. Differentiation of the imaging findings of CT and US, MRI, and MRCP is important to distinguish “bile duct necrosis” from “bile duct dilatation”. Although most cases of BDN and biloma can be treated conservatively, if there are some symptoms such as
moderate or severe infection or interval growth of the biloma, prompt treatment is essential to avoid lethal abscess formation and sepsis.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Deltenre, P.; Valla, D.C. Ischemic cholangiopathy. *Semin. Liver Dis.* 2008, 28, 235–246. [CrossRef]
2. Makuuchi, M.; Sukigara, M.; Mori, T.; Kobayashi, J.; Yamazaki, S.; Hasegawa, H.; Moriyama, N.; Takayasu, K.; Hirohashi, S. Bile duct necrosis: Complication of transcatheter hepatic arterial embolization. *Radiology* 1985, 156, 331–334. [CrossRef] [PubMed]
3. Kobayashi, S.; Nakanuma, Y.; Terada, T.; Matsu, O. Postmortem survey of bile duct necrosis and biloma in hepatocellular carcinoma after transcatheter arterial chemoembolization therapy: Relevance to microvascular damages of peribiliary capillary plexus. *Am. J. Gastroenterol.* 1993, 88, 1410–1415. [PubMed]
4. Atassi, B.; Bangash, A.K.; Lewandowski, R.J.; Ibrahim, S.; Kulik, L.; Mulcahy, M.F.; Murthy, R.; Ryu, R.K.; Sato, K.T.; Miller, F.H. Biliary sequelae following radioembolization with Yttrium-90 microspheres. *J. Vasc. Interim. Radiol.* 2008, 19, 691–697. [CrossRef] [PubMed]
5. Adam, G.; Knoechel, R.; Vorwerk, D.; Held, C.; Gunther, R.W. Tissue response of the biliary and digestive system of rabbits after MTBE infusion into the gallbladder. *Investig. Radiol.* 1990, 25, 58–61. [CrossRef] [PubMed]
6. Hohn, D.C.; Rayner, A.A.; Economou, J.S.; Ignoffo, R.J.; Lewis, B.J.; Stagg, R.J. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. *Cancer* 1986, 57, 465–470. [CrossRef]
7. Shrikhande, S.; Friess, H.; Kleeff, J.; Tempia, A. Bile duct infarction following intraarterial hepatic chemotherapy mimicking multiple liver metastasis: Report of a case and review of the literature. *Dig. Dis. Sci.* 2002, 47, 338–344. [CrossRef]
8. Chung, J.; Yu, J.S.; Chung, J.J.; Kim, J.H.; Kim, K.W. Haemodynamic events and localised parenchymal changes following transcatheter arterial chemoembolisation for hepatic malignancy: Interpretation of imaging findings. *Br. J. Radiol.* 2010, 83, 71–81. [CrossRef] [PubMed]
9. Alabdulghani, F.; Healy, G.M.; Cantwell, C.P. Radiological findings in ischaemic cholangiopathy. *Clin. Radiol.* 2020, 75, 161–168. [CrossRef]
10. Sakamoto, I.; Iwanaga, S.; Nagaoki, K.; Matsuoka, Y.; Ashizawa, K.; Uetani, M.; Fukuda, T.; Okimoto, T.; Okudaira, S.; Omagari, K. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. *Am. J. Roentgenol.* 2003, 181, 79–87. [CrossRef]
11. Wang, Z.; Wang, M.; Duan, F.; Song, P.; Liu, F. Bile Duct Injury after Transcatheter Arterial Chemoembolization: Risk Factors and Clinical Implications. *Hepatogastroenterology* 2014, 61, 947–953. [PubMed]
12. Zhang, B.; Guo, Y.; Wu, K.; Shan, H. Intrahepatic biloma following transcatheter arterial chemoembolization for hepatocellular carcinoma: Incidence, imaging features and management. *Mol. Clin. Oncol.* 2017, 6, 937–943. [CrossRef]
13. Yu, J.S.; Kim, K.W.; Jeong, M.G.; Lee, D.H.; Park, M.S.; Yoon, S.W. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. *Cardiovasc. Intervent. Radiol.* 2002, 25, 270–274. [CrossRef] [PubMed]
14. Vadvala, H.V.; Arellano, R.S. Imaging and Intervention of Biliary Leaks and Bilomas. *Dig. Dis. Intero.* 2017, 1, 14–21.
15. Strazzabosco, M.; Fabris, L. Functional anatomy of normal bile ducts. *Anat. Rec.* 2008, 291, 653–660. [CrossRef] [PubMed]
16. Matsubara, T.; Kozaka, K.; Matsui, O.; Nakanuma, Y.; Uesaka, K.; Inoue, D.; Yoneda, N.; Yoshida, K.; Kitao, A.; Yokka, A. Peribiliary glands: Development, dysfunction, related conditions and imaging findings. *Abdom. Radiol.* 2020, 45, 416–436. [CrossRef]
17. Cho, K.J.; Lunderquist, A. The peribiliary vascular plexus: The microvascular architecture of the bile duct in the rabbit and in clinical cases. *Radiology* 1983, 147, 357–364. [CrossRef]
18. Kobayashi, S.; Nakanuma, Y.; Matsu, O. Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases: A histological survey. *Hum. Pathol.* 1994, 25, 940–946. [CrossRef]
19. Takasaki, S.; Hano, H. Three-dimensional observations of the human hepatic artery (Arterial system in the liver). J. Hepatol. 2001, 34, 455–466. [CrossRef]
20. Gaudio, E.; Franchitto, A.; Pannarale, L.; Carpino, G.; Alpini, G.; Francis, H.; Glaser, S.; Alvaro, D.; Onori, P. Cholangiocytes and blood supply. World J. Gastroenterol. 2006, 12, 3546–3552. [CrossRef]
21. Kobayashi, S.; Nakamura, Y.; Matsui, O. Histopathology of portal tracts in livers after transcatheter arterial chemo-embolization therapy for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1994, 9, 45–54. [CrossRef]
22. Rao, R.K.; Samak, G. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 2013, 1, e25718. [CrossRef]
23. Perez, M.J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15, 1677–1689. [CrossRef]
24. Xia, X.; Francis, H.; Glaser, S.; Alpini, G.; LeSage, G. Bile acid interactions with cholangiocytes. World J. Gastroenterol. 2006, 12, 3533–3563. [CrossRef] [PubMed]
25. Beuers, U.; Hohenester, S.; de Buy Wenniger, L.J.; Kremer, A.E.; Jansen, P.L.; Elferink, R.P. The biliary HCO(3)(-) umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010, 52, 1489–1496. [CrossRef] [PubMed]
26. Melero, S.; Spirli, C.; Zsembely, A.; Medina, J.F.; Joplin, R.E.; Duner, E.; Zuin, M.; Neuberger, J.M.; Prieto, J.; Strazzabosco, M. Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 2002, 35, 1513–1521. [CrossRef] [PubMed]
27. Chen, G.; Wang, S.; Bie, P.; Li, X.; Dong, J. Endogenous bile salts are associated with bile duct injury in the rat liver transplantation model. Transplantation 2009, 87, 330–339. [CrossRef]
28. Deltenre, P.; Valla, D.C. Ischemic cholangiopathy. J. Hepatol. 2006, 44, 806–817. [CrossRef] [PubMed]
29. Phongkitkarun, S.; Kobayashi, S.; Varavithya, V.; Huang, X.; Curley, S.A.; Charnsangavej, C. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin. Radiol. 2005, 60, 700–709. [CrossRef]
30. Cameron, A.M.; Busuttil, R.W. Ischemic cholangiopathy after liver transplantation. Hepatobiliary Pancreat Dis. Int. 2005, 4, 495–501. [CrossRef]
31. Cheng, L.; Zhao, L.; Li, D.; Liu, Z.; Chen, G.; Tian, F.; Li, X.; Wang, S. Role of cholangiocyte bile Acid transporters in large bile duct injury after rat liver transplantation. Transplantation 2010, 90, 127–134. [CrossRef] [PubMed]
32. Boteon, A.P.C.d.; Boteon, Y.L.; Vinuela, E.F.; Derosas, C.; Mergental, H.; Isaac, J.R.; Muiesan, P.; Mehzard, H.; Ma, Y.T.; Shah, T. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study. Clin. Transplant. 2018, 32, e13255. [CrossRef] [PubMed]
33. Guo, S.H.; Li, C.H.; Chen, Y.L.; Song, J.N.; Zhang, A.Q.; Zhou, C. Effects of partial portal vein arterialization on the hilar bile duct in a rat model. Hepatobiliary Pancreat Dis. Int. 2011, 10, 533–538. [CrossRef]
34. Keppler, U.; Moussavain, M.R.; Jeanmonod, P.; Strowitzki, M.J.; Wagner, M.; Scheuer, C.; Mengen, M.D.; von Heesen, M. Neither Isolated Hepatic Arterial Clamping nor Hepatic Arterial Ligation Induce Ischemic Type Biliary Lesions in Rats. Ann. Transplant 2016, 21, 649–659. [CrossRef] [PubMed]
35. Miyayama, S.; Yamashiro, M.; Hashimoto, M.; Hashimoto, N.; Ikuno, M.; Okumura, K.; Yoshida, M.; Matsui, O. Blood supply of the main bile duct from the caudate artery and medial subsegmental artery of the hepatic artery: Evaluation using images obtained during transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol. Res. 2013, 43, 1175–1181. [CrossRef]
36. Yu, J.S.; Kim, K.W.; Park, M.S.; Yoon, S.W. Bile duct injuries leading to portal vein obliteration after transcatheter arterial chemoembolization in the liver: CT findings and initial observations. Radiology 2001, 221, 429–436. [CrossRef]
37. Spina, J.C.; Ulla, M.; Yeyati, E.L.; Kucharczyk, M.C.; Irusta, H.; Savuk, J.L.; Garcia-Mónaco, R. MDCT findings after hepatic chemoembolization with DC-beads: What the radiologist needs to know. Abdom. Imaging 2013, 38, 778–784. [CrossRef]
38. Kitao, A.; Zen, Y.; Matsui, O.; Gabata, T.; Kobayashi, S.; Koda, W.; Kozaka, K.; Yoneda, N.; Yamashita, T.; Kaneko, S.; et al. Hepatocellular carcinoma: Signal intensity at gadoxetic acid-enhanced MR Imaging—correlation with molecular transporters and histopathologic features. Radiology 2010, 256, 817–826. [CrossRef]
39. Geisel, D.; Lüdemann, L.; Hamm, B.; Denecke, T. Imaging-Based Liver Function Tests—Past, Present and Future. Rofo 2015, 187, 863–871. [CrossRef]
40. Cieszanowski, A.; Stadnik, A.; Lezak, A.; Maj, E.; Zieniewicz, K.; Rowinska-Berman, K.; Grudzinski, I.P.; Krawczyk, M.; Rowinski, O. Detection of active bile leak with Gd-EOB-DTPA enhanced MR cholangiography: Comparison of 20–25 min delayed and 60–180 min delayed images. *Eur. J. Radiol.* **2013**, *82*, 2176–2182. [CrossRef]

41. Margini, C.; Berzigotti, A. Portal vein thrombosis: The role of imaging in the clinical setting. *Dig. Liver Dis.* **2017**, *49*, 113–120. [CrossRef]

42. Elsayes, K.M.; Shaaban, A.M.; Rothan, S.M.; Javadi, S.; Madrazo, B.L.; Castillo, R.P.; Casillas, V.J.; Menias, C.O. A Comprehensive Approach to Hepatic Vascular Disease. *Radiographics* **2017**, *37*, 813–836. [CrossRef][PubMed]

43. Ide, T.; Ohno, Y.; Nakanuma, Y.; Kanematsu, T. Early development of cavernomatous vasculatures in portal venous thrombosis: Morphometric kinetics in rabbit model. *Hepatol. Res.* **2003**, *27*, 136–142. [CrossRef]

44. Modha, K. Clinical Approach to Patients with Obstructive Jaundice. *Tech. Vasc. Interv. Radiol.* **2015**, *18*, 197–200. [CrossRef][PubMed]

45. Hoshiba, K.; Matsui, O.; Kadoya, M.; Yoshikawa, J.; Gabata, T.; Terayama, N.; Takashima, T. Peribiliary cysts in cirrhotic liver: Observation on computed tomography. *Abdom. Imaging* **1996**, *21*, 228–232. [CrossRef]

46. Brancatelli, G.; Federle, M.P.; Vilgrain, V.; Vullierme, M.P.; Marin, D.; Lagalla, R. Fibropolycystic liver disease: CT and MR imaging findings. *Radiographics* **2005**, *25*, 659–670. [CrossRef]

47. Choi, B.I.; Yeon, K.M.; Kim, S.H.; Han, M.C. Caroli disease: Central dot sign in CT. *Radiology* **1990**, *174*, 161–163. [CrossRef]